ChromoCure to Secure Patents on Proprietary Chromosomal Cancer Detection Technology as Foundation in Preparation for Cancer Ther
2010年1月27日 - 10:30PM
Marketwired
ChromoCure, Inc. (PINKSHEETS: KKUR) -- The Company announced today,
based on the recent validation of its cancer detection approach and
efficacy of its proprietary Chromosomal Scanning Technology, that
it has retained Patent & Intellectual Property Attorneys to
assess its growing Intellectual Property portfolio and secure
necessary filings and Patent protections. A complex and innovative
series of systems, processes, cell preparation techniques and
diagnostic algorithms are currently integrated in ChromoCure's
landmark Chromosomal Scanning Technology.
The Company recently announced it will accelerate the
implementation of its Cancer Therapy and Cure initiatives. The
Intellectual Property audit and subsequent Patent Applications and
protections will provide the required foundation for various
research programs and collaborations.
ChromoCure's chromosomal approach to cancer detection, therapy
and cure has been validated by recent publications, including the
Mayo Clinic findings. Per the publication of the company's clinical
collaboration and testing, its proprietary Chromosomal Scanner
technology was demonstrated a reliable and effective automated
technological system to detect aneuploid cells in real-world
specimens, that detection of aneuploid cells is diagnostic of
cervical lesions and that the Chromosomal Scanner possesses superb
performance at not only detecting cancer but achieving the near
theoretical maximum agreement with the collaborating clinic's error
containing data.
The Company's pioneering knowledge of cancer's chromosomal
properties invites very effective, non-toxic therapeutic
strategies. ChromoCure's understanding of cancer's chromosomal
peculiarities provides the most promising avenue for treatment and
cure and reinforces its pioneering status.
About ChromoCure
ChromoCure develops and provides proprietary cancer detection
systems and technologies. The Company's proprietary ChromoCure
CS200 Chromosomal Scanner system has been proven accurate and
efficient in the measurement of the unique genomic characteristic
found in 100% of all cancers and never found in normal cells. The
Company's technology has been proven to have an effective accuracy
of 100% for all cancers at all stages and believes its technology
will become the worldwide gold standard for cancer detection,
progression measurement, and research for both therapy and
cure.
Safe-Harbor Statement
This release contains statements or projections regarding future
performance that is forward-looking statements as defined in the
Private Securities Litigation Reform Act of 1995. Actual results
may differ materially from those projected as a result of certain
risks and uncertainties. The company's filings contain various RISK
FACTORS (and are incorporated herein by reference) and should be
read before any investment decision.
Contact: ChromoCure, Inc. www.ChromoCure.com info@chromocure.com
Tel 1.775.636.654
Chromocure (CE) (USOTC:KKUR)
過去 株価チャート
から 5 2024 まで 6 2024
Chromocure (CE) (USOTC:KKUR)
過去 株価チャート
から 6 2023 まで 6 2024
Real-Time news about Chromocure Inc (CE) (その他OTC): 0 recent articles
その他のChromoCure, Inc.ニュース記事